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Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30),
a PRO instrument specifically designed to measure HRQoL of cancer patients.
HRQoL was measured at screening, months 1, 3, 7, and at re-puncture. Meaningful
deterioration was defined as a decrease in HRQoL scores of at least 5 points. Time
to first meaningful deterioration was compared between catumaxomab (N160)
and control (N85) groups using survival analysis techniques such as log-rank test
and Cox models. RESULTS: Deterioration in HRQoL scores appeared more rapidly
in the control group than the catumaxomab group (medians: 16-28 days vs. 45-49
days). The difference between the two groups in time to deterioration in HRQoL
was statistically significant for all scores (p0.01). Results were confirmed with Cox
models (p0.05). Hazard ratios ranged from 0.08 to 0.24.CONCLUSIONS:Treatment
with catumaxomab delayed deterioration in HRQoL in patients with MA compared
to paracentesis alone. The findings of this study indicate that the gain of puncture
free survival due to catumaxomab treatment previously reported (Heiss et al. 2010)
translates into a HRQoL benefit for the patients.
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OBJECTIVES: The majority of patients with prostate cancer progress to CRPC and
frequently develop bone metastases. Treatment and management of bone metas-
tases, as well as the underlying disease, influences the patient’s quality of life. We
evaluated the impact of bone metastases on utility (using EQ-5D) and quality of life
(using FACT-P) in high-risk CRPC patients. METHODS: Data were extracted from
the Adelphi Real World Prostate Cancer Disease-Specific Programme© (DSP), a
cross-sectional survey of 348 urologists and oncologists and their prostate cancer
patients that was conducted between December 2009 and May 2010 in France,
Germany, Italy, Spain and the UK. Physicians completed comprehensive record
forms on 10 patients being actively treated for prostate cancer. Patients could also
complete a questionnaire, which included the EQ-5D and FACT-P tools, however
this was not compulsory. RESULTS:Of the 3,477 prostate cancer patients for which
data were collected, 1,180 (34%) were categorised as having CRPC with a median
time since diagnosis of 35.8 months. 146 patients with CRPC were identified as
being at high risk for developing bone metastases (Gleason score 8, or a most
recent PSA of 8ng/mL, or a PSA DT 10 months, or had received local therapy in
addition to systemic medication). High-risk CRPC patients had an average EQ-5D
index of 0.77 (n36) and FACT-P of 99.54 (n27). In contrast, patients with CRPC
and bone metastases (n680) had an average EQ-5D index of 0.59 (n165) and
FACT-P of 82.99 (n147). Statistical differences were observed between the high-
risk and bone metastases groups for both EQ-5D (p0.0002) and FACT-P (p0.0007).
CONCLUSIONS: The development of bone metastases represents a significant ad-
ditional burden for patients with CRPC highlighting the need for new treatments
capable of preventing bone metastases in these patients.
PCN119
PATIENT-REPORTED OUTCOMES (PROS) IN ANTINEOPLASTIC PRODUCT
APPROVALS IN EUROPE AND IN THE USA
Patrick D1, Acquadro C2, Teschendorf B3, Emery MP2, Caron M2, Arnould B4
1University of Washington, Seatte, WA, USA, 2MAPI Research Trust, Lyon, France, 3Adelphi
Values, Boston, MA, USA, 4MAPI Consultancy, Lyon, France
OBJECTIVES: (1) To identify antineoplastic agents approved with a PRO labeling
claim in Europe and the USA; (2) To review the types of PROs used for these ap-
provals; and (3) To list the differences found between Europe and the USA in terms
of products and labeling. METHODS: The search was performed on the FDA and
EMA approved medicinal product labels (from 1995 to 2010). The review was con-
ducted through a systematic manual review of antineoplastic product labelings. All
documents were read individually by two independent raters. RESULTS: A total of
138 antineoplastic products were retrieved: 55 approved by the EMA, 83 by the FDA.
Nineteen products with a PRO claim were identified: eight the USA, 11 in Europe.
Most of the PROs identified in the claims were symptoms or function. HRQL was
mentioned for 11 products: nine in Europe, two in the USA. PROs were primary
endpoints in two cases (advanced cancers). Nine products approved by both agen-
cies showed discrepancies in terms of PRO labeling: the EMA gave a PRO claim to
eight products, but not the FDA; and the FDA gave a PRO claim to one product, but
not the EMA. In most cases, the reviews of both agencies were conducted on the
same material. The comparison of the products with a PRO labeling claim approved
by the EMA but refused by the FDA showed that the FDA questioned the quality of
the study design, the analyses, or the questionnaires’ content validity.
CONCLUSIONS: Our review showed that the patients’ perspective in clinical onco-
logic research is important for the EMA and FDA. However, the patients’ perspec-
tive is not considered sufficient on its own: PROs are rarely used as primary end-
points except for assessing palliative response. Our analysis suggests that there is
high receptivity of EMA to HRQL as a concept.
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Treatment of metastatic castration-resistant prostate cancer (mCRPC) is primarily
palliative and patients’ quality of life (QoL) is considered an important treatment
goal. Nevertheless, little is known about QoL of mCRPC patients. OBJECTIVES: To
assess QoL outcomes in mCRPC patients in Germany. METHODS: 1-year observa-
tional, cross-sectional, prospective study conducted in Germany by 37 prostate-
cancer (PC) specialised centres. The study included patients with confirmed PC
diagnosis and metastatic castration-resistant disease. EQ-5D and FACT-P ques-
tionnaires were completed by patients at inclusion visit. Patient characteristics
were collected by physicians. Interim results based on 101 of 281 patients in total,
are presented. RESULTS: Mean age was 73.2 years. At inclusion, 32.6% had never
been treated with chemotherapy (no CT), 36.8% had been treated with chemother-
apy previously (past CT) and 30.5% were currently undergoing chemotherapy (on-
going CT). Mean time since PC diagnosis was 7.2 years (respectively 8.7, 6.6 and 4.0
years for no CT, past CT and ongoing CT). 34.0% of patients had metastases at
diagnosis. Mean (SD) EQ-5D single index utility score was 0.72 (0.30) (respectively
0.81 (0.27), 0.66 (0.30), 0.64 (0.31) for no CT, past CT and ongoing CT). 67.3% of
patients exhibited pain or discomfort, 58.1% problems to perform usual activities,
53.1% mobility problems, 37.7% anxiety/depression troubles and 32.7% self-care
problems. Mean (SD) EQ-5D VAS score was 47.8 (23.6). Mean (SD) FACT-P total score
was 101.5 (25.2) (respectively 106.0 (27.1), 95.2 (21.6) and 103.5 (26.7) for no CT, past
CT and ongoing CT). Mean (SD) subscale scores were: physical well-being: 19.5 (6.6),
social/family well-being: 20.6 (5.6), emotional well-being: 17.0 (4.8), functional well-
being: 15.7 (6.3) and PC subscale: 28.6 (9.0). CONCLUSIONS: The interim analysis
provides first trends on QoL in German mCRPC patients. Final analyses are ex-
pected to clarify determinants of QoL and in particular the impact of chemother-
apy.
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OBJECTIVES: The incidence of acute myeloid leukaemia (AML) increases with age;
older patients have limited treatment options and poorer outcomes. Dependence
on blood transfusions (correcting anaemia and preventing bleeding) and repeated
hospitalisation reduce health-related quality of life and increase treatment expen-
diture. This post-hoc analysis assessed the impact of decitabine on transfusion
dependence.METHODS:The DACO-16 phase III trial (NCT00260832) was conducted
in newly-diagnosed AML patients (65 years; N485) (Kantarjian, JCO; ePub
11Jun2012). Every 4 weeks, patients received decitabine (DACOGEN) 20 mg/m2 (1-h
intravenously; 5 successive days) or treatment choice with physician’s advice (TC)
with supportive care or cytarabine (20 mg/m2 subcutaneously daily; 10 successive
days). Treatment duration was longer in the DACOGEN than TC arm (median: 4
cycles vs. 2 cycles). We measured red blood cell (RBC) and platelet (PLT) transfu-
sion-independence (no transfusions for 8 consecutive weeks) and hospitalisation
length (% hospital nights relative to treatment days) in both DACOGEN (n242) and
TC (n243) arms. RESULTS: In patients who were PLT transfusion-dependent at
baseline (85 in DACOGEN and 83 in TC arms), more became transfusion-indepen-
dent in the DACOGEN arm (26 [31%]) than the TC arm (11 [13%]) (p0.0069). Like-
wise, in RBC transfusion-dependent patients at baseline (168 in DACOGEN and 162
in TC arms), transfusion-independence was higher for DACOGEN (44 [26%]) than TC
(21 [13%]) (p0.0026). For hospitalised patients (182 in TC, 191 in DACOGEN arms),
the median % of hospital nights was higher in the TC arm (39%) than the DACOGEN
arm (34%). Similarly, for adverse event-hospitalised patients (100 in TC, 132 in
DACOGEN arms), the median was 20.0% vs. 17.5% in the TC and DACOGEN arms,
respectively. CONCLUSIONS: Dacogen leads to a statistically-significant reduction
in transfusion-dependence, when compared with TC. This reduction is an impor-
tant factor in the economic and humanistic burden of AML in older patients.
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OBJECTIVES: G-CSFs can decrease the incidence of febrile neutropenia (FN) among
cancer patients receiving highly myelosuppressive chemotherapy regimens. The
primary objective of this pilot study was to determine the feasibility of a discrete
choice survey on prophylactic G-CSF (pegfilgrastim and filgrastim) use in patients
diagnosed with breast cancer as well as refine the survey instrument before pro-
ceeding with the full study population. METHODS: A web-based discrete choice
survey of patients diagnosed with breast cancer, and previously treated with che-
motherapy, was conducted. The pilot survey was developed based on literature
review, clinical consultation and 6 in-depth and 4 pre-test interviews with breast
cancer patients. The experimental design was generated using Sawtooth software
with 16 paired treatment-scenarios, comparing pegfilgrastim to filgrastim at 6- or
11-doses with a follow-up “no treatment” option. The 5 attributes included: fre-
quency of treatment, inconvenience of treatment, risk of disruption to chemother-
apy schedule due to low white blood cell counts, risk of developing an infection
requiring hospitalization, and patient out-of-pocket cost. Demographics, clinical
characteristics, health care costs and attitudinal data were also collected.
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RESULTS: The responses from 29 of the thirty-two patients (91%) surveyed were
analyzed. Most patients were able to answer questions regarding FN, including
whether their health care provider had discussed, and if they had received, any FN
prophylaxis (81% and 60%, respectively). The attribute with the most impact on
patient’s choices was “risk of developing an infection”; whereas “inconvenience of
treatment” had the least impact and was likely confounded with “frequency of
treatment.” The median completion time was 13 minutes. CONCLUSIONS: The
pilot study results suggest that the survey is feasible in the breast cancer popula-
tion. The only change to the survey instrument will be the removal of the attribute
“inconvenience of treatment”; otherwise, the 16 treatment-scenario design, in-
cluding the “no treatment” option, will be maintained.
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OBJECTIVES: Metastatic breast cancer (MBC) patients are treated with a variety of
regimens with differing side effects that can reduce the patients’ quality of life.
Conjoint analysis is a research method used to evaluate how trade-offs are made
between different attributes. This study assessed the willingness to pay (WTP) to
avoid side effects related to MBC treatment using conjoint analysis. METHODS: An
online, self-administered conjoint analysis survey of US adult female MBC patients
was conducted to elicit preferences for MBC treatment side effects. Attributes in-
cluded in the analysis with levels described in lay terms were: Alopecia, Diarrhea,
Fatigue, Nausea, Neuropathy, Pain, Neutropenia and Out of pocket costs. 15 choice-
based conjoint questions were presented where patients selected the most pre-
ferred therapy. A partial profile design was used to allow for each treatment de-
scription to be made with 3 instead of all 8 attributes. The attribute choices for each
question included two side effects and an out of pocket price. The survey also
collected information on prior treatment regimens, previous side effect history,
and demographics. RESULTS: There were 298 respondents. Most respondents were
white (84%), married (57%) over 40 years of age (86%), and covered with private
insurance (57%). MBC patients were WTP (US$) $3,894 to avoid severe diarrhea,
$3,479 to avoid being hospitalized due to infection, $3,211 to avoid severe nausea,
$2,764 to avoid severe tingling in hands and feet, $2,652 to avoid severe fatigue,
$1,853 to avoid obvious hair loss and $1,458 to avoid severe pain. The most impor-
tant attributes when selecting a therapy for MBC in terms of average utility were
neutropenia, diarrhea and nausea. CONCLUSIONS: Patients most highly value the
avoidance of diarrhea, neutropenia, and nausea with MBC treatment regimens.
Additional research with a global patient population is needed to quantify the WTP
to avoid MBC side effects.
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OBJECTIVES: Cancer more than other diseases concerns not only patients them-
selves, but also close relatives of patients. The aim of this study was to estimate lost
productivity in a population of close relatives of cancer patients who provide them
with home care. METHODS: Survey on a representative sample of Polish econom-
ically active population of close relatives to cancer patients was planned. To assess
the impact of cancer on productivity of relatives to cancer patients a modified
questionnaire WPAI-SHP was used. The WHO performance scale was used to as-
sess general health status of cancer patients. Human capital approach was used to
estimate the absenteeism and presenteeism costs. Values are presented in Euro
(exchange rate: 1 EUR4.20 PLN). RESULTS: A total of 23,518 persons were ques-
tioned between August 2011 and April 2012. Of them 112 (0.48%) met inclusion
criteria and completed WPAI-SHP questionnaire but only 98 persons completed
questionnaire properly and were finally included in calculation. The mean age of
included persons was 40.212.5 years and the average declared weekly work time
was 42.714.1 hours. The average percent work time missed due to close relatives
cancer was 4.7% and corresponded to a weekly average time of the absence of 1.9
hours. In contrast, the percent of working impairment due to cancer of close rela-
tives was estimated at 21.0% and corresponded to weekly average productivity loss
of 7.3 hours. When projected on total population, the estimated indirect costs
associated with absenteeism amounted to about 154.5 million EUR and were sig-
nificantly lower than the estimated costs of presenteeism – 607.4 million EUR.
CONCLUSIONS: The analysis showed that the loss of productivity in a population
of close relatives of cancer patients have important implications for the Polish
economy, however less pronounced than costs of productivity loss measured in
cancer population (1,935 billion EUR).
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OBJECTIVES: We previously reported that indirect costs of absenteeism in the
workplace owing to cancer are almost twice as high as the estimated direct costs of
cancer treatment in Poland. Although approximately 60% of the absenteeism costs
were caused by premature mortality, to gain a full understanding of the indirect
costs of lost productivity the presenteeism in the workplace must be analyzed.
METHODS: Survey on a population of about 300 economically active patients (score
80 or above on Karnofsky performance scale) with cancer was planned at 10 re-
gional oncology centers in Poland. To assess the impact of health on productivity a
modified questionnaire WPAI-SHP was used. Due to the considerable heterogene-
ity of the study group and given the limited number of respondents we have re-
frained from collecting data on clinical characteristics of the disease. Human cap-
ital approach was used to estimate the presenteeism costs. Values are presented in
Euro (exchange rate: 1 EUR4.20 PLN). RESULTS: Data on 299 patients were col-
lected. The mean age of surveyed patients was 51 years and the average declared
weekly work time was 41 hours. The average time of the absence from work due to
cancer in the study population was 7.69.9 hours. The estimated average loss of
productivity in the workplace was 37.3%, corresponding to 10.38.5 loss of hours of
work. When projected on total economically active population with cancer, the
estimated indirect costs associated with the presenteeism amounted to about 363
million EUR and were significantly lower than the previously estimated costs of
sickness absence (1,572 million EUR).CONCLUSIONS:The analysis showed that the
loss of productivity associated with the presenteeism among cancer patients has
important implications for the Polish economy but less pronounced than costs of
absenteeism in the workplace. This study was funded by the Ministry of Science and
Higher Education grant no. N N405 115034.
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OBJECTIVES: Dutch policy requires evidence from outcomes research for the as-
sessment of appropriate drug use and real-world cost-effectiveness. We investi-
gated whether a population-based patient registry could improve the feasibility of
outcomes research in multiple myeloma compared to a retrospective cohort study.
METHODS: Two methods were used to investigate the feasibility of outcomes re-
search. First, we conducted outcomes research for bortezomib in multiple my-
eloma (n139) by retrospectively collecting detailed data from hospital medical
records in 38% of all Dutch hospitals. Second, we conducted outcomes research by
using a population-based registry for haematological malignancies (PHAROS) cov-
ering 40% of the Netherlands. Up till now, the registry contains 3093 patients,
including 802 patients with multiple myeloma. RESULTS: In the retrospective bort-
ezomib study, it was possible to gather data on drug and resource use in everyday
practice. However, due to great patient heterogeneity, extensive treatment varia-
tion (10 drugs in20 combinations) and missing prognostic information (e.g. 71%
missing serum 2-microglobulin levels), it was impossible to estimate incremental
cost-effectiveness of bortezomib. The PHAROS population-based registry also pro-
vided data on drug and resource use in everyday practice. Like the retrospective
study, the registry revealed extensive treatment variation. This, in combination
with great patient heterogeneity, challenged the feasibility to identify appropriate
groups of comparable patients to calculate cost-effectiveness. CONCLUSIONS:
Compared to a clinical trial, outcomes research in multiple myeloma is compli-
cated by extensive treatment variation and wide patient heterogeneity. The
PHAROS registry provides better generalisable outcomes research results, but
many challenges remain in data analysis. Nevertheless, the greater number of
real-world patients might provide the opportunity to obtain a sufficiently valid
cost-effectiveness estimate by using comprehensive modeling techniques and dif-
ferent data sources.
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OBJECTIVES: Dutch policy regulations for expensive inpatient drugs require out-
comes research for the assessment of appropriate drug use and cost-effectiveness
after four years of temporary reimbursement. We investigated whether outcomes
research of bortezomib in advanced multiple myeloma reduced decision makers’
uncertainty. METHODS: Our cohort study included 139 patients who were treated
for advanced multiple myeloma outside of a clinical study. Detailed data were
retrospectively collected from medical records in 38% of all Dutch hospitals.
RESULTS: It was possible to develop evidence on types of drug used, dosages, dose
modifications and health care costs. However, it was impossible to identify a single
treatment comparator (10 drugs in 20 combinations), partly due to rapid devel-
opments in treatment for multiple myeloma. Moreover, patients treated with bort-
ezomib (n72) were not comparable to other patients (n67) regarding prognostic
factors. It was not clear whether physicians used standardised outcome measures
(i.e. EBMT response and CTC toxicity criteria) since such information was often not
reported in medical records. Although different adjustment techniques were ap-
plied to the Cox multivariate regression model to obtain a valid (overall) survival
estimate, none succeeded in correcting for the observed confounding. Moreover,
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